Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

AS Chi, RS Tarapore, MD Hall, N Shonka… - Journal of neuro …, 2019 - Springer
Background H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven
medical therapies. The entity predominantly occurs in children and young adults. ONC201 is …
被引用次数：195 相关文章

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

AS Chi, RS Tarapore, MD Hall… - Journal of neuro …, 2019 - pubmed.ncbi.nlm.nih.gov
Background H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven
medical therapies. The entity predominantly occurs in children and young adults. ONC201 is …

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

AS Chi, RS Tarapore, MD Hall… - Journal of neuro …, 2019 - scholar.barrowneuro.org
BACKGROUND: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no
proven medical therapies. The entity predominantly occurs in children and young adults …

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

AS Chi, RS Tarapore, MD Hall… - Journal of Neuro …, 2019 - scholars.northwestern.edu
Background: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven
medical therapies. The entity predominantly occurs in children and young adults. ONC201 is …

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

AS Chi, RS Tarapore, MD Hall… - Journal of Neuro …, 2019 - search.proquest.com
Background H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven
medical therapies. The entity predominantly occurs in children and young adults. ONC201 is …

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

AS Chi, RS Tarapore, MD Hall… - Journal of Neuro …, 2019 - experts.nebraska.edu
Background: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven
medical therapies. The entity predominantly occurs in children and young adults. ONC201 is …

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.

A Chi, R Tarapore, M Hall, N Shonka… - Journal of Neuro …, 2019 - escholarship.org
BACKGROUND: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no
proven medical therapies. The entity predominantly occurs in children and young adults …
[HTML] nih.gov

[HTML][HTML] Pediatric and Adult H3 K27M-mutant Diffuse Midline Glioma Treated with the Selective DRD2 Antagonist ONC201

AS Chi, RS Tarapore, MD Hall, N Shonka… - Journal of neuro …, 2019 - ncbi.nlm.nih.gov
Background: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven
medical therapies. The entity predominantly occurs in children and young adults. ONC201 is …

[引用][C] Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

AS Chi, RS Tarapore, MD Hall, N Shonka… - Journal of Neuro …, 2019 - cir.nii.ac.jp
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2
antagonist ONC201 | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Pediatric and Adult H3 K27M-mutant Diffuse Midline Glioma Treated With the Selective DRD2 Antagonist ONC201

D Daghistani, AS Chi, R Tarapore… - Journal of neuro …, 2019 - baptisthealth.elsevierpure.com
Pediatric and Adult H3 K27M-mutant Diffuse Midline Glioma Treated With the Selective DRD2
Antagonist ONC201 — Baptist Health South Florida's Research Portal Skip to main navigation …